ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Dextromethorphan

Also written as “dextromethorphan”, “Drug Cocktail” and “AVP-923-20”.

Its studies are mostly in Neoplasm Metastasis · Multiple Sclerosis · Cough · Nasal Obstruction · Diabetes Mellitus, Type 2, led by 4 companies.

Drug pageDextromethorphan: every studyAll 81 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Feb 25, 20138 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka40 open or runningphase 4since Feb 25, 2013Dec 13, 2007none ahead
Pfizerits history only20 open or runningphase 4since Dec 7, 2010Dec 7, 2010none ahead
Johnson & Johnsonits history only10 open or runningphase 3since Jan 15, 2018Jan 15, 2018none ahead
Profil Institut für Stoffwechselforschungits history only10 open or runningphase 2since Aug 28, 2013Aug 28, 2013none ahead

Also a collaborator on its studies: Parexel, Boehringer Ingelheim, Novartis, Perrigo, Procter and Gamble and Reckitt.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Otsuka only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 13, 2007First study: phase 3 study in Amyotrophic Lateral SclerosisFirst studyNCT00573443 · 326 enrolled · United States, Argentina, Brazil
  2. Mar 23, 2011Phase 2 study in Multiple SclerosisNCT01324232 · 209 enrolled · United States, Argentina, Czechia and more
  3. Feb 25, 2013Phase 4 study in StrokeNCT01799941 · 367 enrolled · United States
  4. Jul 8, 2015Phase 4 study in Pseudobulbar Affect (Involuntary Laughing and/or Crying)NCT02496039 · 5 enrolled · United States

TargetBeta

“Sigma opioid receptor agonist; Sigma opioid receptor agonist; Glutamate [NMDA] receptor subunit epsilon 1 antagonist; Glutamate [NMDA] receptor subunit epsilon 1 antagonist”ChEMBL 37, by rule

Studies

All 4 Otsuka leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02496039Pseudobulbar Affect (Involuntary Laughing and/or Crying) · United States4TerminatedMay 20165
NCT01799941Stroke · United States4CompletedMay 2015367
NCT01324232Multiple Sclerosis · United States, Argentina, Czechia and more2CompletedSep 26, 2013209
NCT00573443Amyotrophic Lateral Sclerosis · United States, Argentina, Brazil3CompletedJun 2009326

How it is read

Names in the registry

  • “Dextromethorphan”, 6 entries
  • “dextromethorphan”, 1 entry
  • “Drug Cocktail”, 1 entry
  • “AVP-923-20”, 1 entry
  • “Dextromethorphan Hydrobromide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.